BWX Technologies, Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

JPMorgan Chase & Co. Initiates Coverage on BWX Technologies (NYSE:BWXT)

AI-generated analysis

πŸ“ˆ JPMorgan initiates coverage with an 'overweight' rating and a $230.00 price target, implying 35.89% upside from current levels.

πŸ’° Q1 earnings beat consensus significantly with $1.12 EPS versus the $0.92 estimate and revenue of $860.22 million.

πŸ“Š Revenue grew 26.1% year-over-year, driven by strong performance in nuclear propulsion and commercial markets.

🎯 Company guidance for FY 2026 EPS ranges from $4.60 to $4.75, aligning with analyst forecasts of $4.60.

πŸ“‰ CFO Michael Thomas Fitzgerald sold 2,417 shares worth approximately $505,757 under a Rule 10b5-1 plan.

πŸ“‰ CEO Rex D. Geveden sold 10,000 shares worth approximately $2.05 million under a pre-arranged trading plan.

πŸ›οΈ Institutional investors hold 94.39% of the company's outstanding shares, indicating strong institutional confidence.

πŸš€ BWXT is expanding its portfolio with small modular reactors (SMRs) and medical radioisotope production capabilities.

βš–οΈ Analyst consensus remains 'Moderate Buy' with an average price target of $228.20 across multiple research firms.

Bullish Signals
  • JPMorgan Chase initiated coverage with an 'overweight' rating and a $230.00 price target, signaling strong institutional confidence in the company's growth prospects.
  • The company reported quarterly EPS of $1.12, significantly topping the consensus estimate of $0.92, demonstrating robust operational performance.
  • Revenue reached $860.22 million, exceeding analyst expectations of $837.47 million and growing 26.1% compared to the same quarter last year.
  • BWX Technologies maintains a healthy net margin of 10.20% and an impressive return on equity of 31.33%, indicating efficient capital utilization.
  • The company has set forward-looking guidance for FY 2026 EPS between $4.60 and $4.75, providing clear visibility into future earnings potential.
  • Institutional ownership stands at 94.39%, with recent acquisitions from firms like WFA of San Diego LLC and MV Capital Management Inc., reflecting sustained investor interest.
Risk Factors
  • CFO Michael Thomas Fitzgerald sold 2,417 shares worth approximately $505,757, representing a 25.99% decrease in his personal position.
  • CEO Rex D. Geveden sold 10,000 shares worth approximately $2.05 million, reducing his holdings by 4.71% under a pre-arranged trading plan.
Full Analysis
JPMorgan Chase & Co. initiated coverage on BWX Technologies (NYSE:BWXT) with an 'overweight' rating and a $230.00 price target, suggesting potential upside of 35.89% from the current price. This follows a mixed analyst landscape where other firms like Weiss Ratings and Seaport Research Partners have issued buy ratings, while Wells Fargo holds an underweight stance and Zacks Research recently cut its rating to hold. The company reported strong quarterly earnings on May 4th, beating consensus estimates with $1.12 EPS against a forecast of $0.92 and revenue of $860.22 million versus an expected $837.47 million. Key financial metrics included a net margin of 10.20%, a return on equity of 31.33%, and quarterly revenue growth of 26.1% year-over-year, with the company guiding for FY 2026 EPS between $4.60 and $4.75. Recent insider activity saw CFO Michael Thomas Fitzgerald sell 2,417 shares at an average price of $209.25 and CEO Rex D. Geveden sell 10,000 shares at $204.81, both transactions executed under pre-arranged Rule 10b5-1 trading plans. Institutional ownership remains high at 94.39%, with recent quarter acquisitions noted from WFA of San Diego LLC, MV Capital Management Inc., and Tucker Asset Management LLC. BWX Technologies operates as a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. Its core business involves designing and fabricating nuclear propulsion systems for the U.S. Navy, while also developing small modular reactors (SMRs) and producing medical radioisotopes for diagnostic imaging and cancer treatment.